(NASDAQ: EMBC) Embecta's forecast annual revenue growth rate of 2.99% is not forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.74%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.33%.
Embecta's revenue in 2026 is $1,018,700,000.On average, 6 Wall Street analysts forecast EMBC's revenue for 2027 to be $62,495,537,697, with the lowest EMBC revenue forecast at $60,002,515,341, and the highest EMBC revenue forecast at $64,478,623,662. On average, 5 Wall Street analysts forecast EMBC's revenue for 2028 to be $62,835,495,291, with the lowest EMBC revenue forecast at $59,945,855,742, and the highest EMBC revenue forecast at $64,931,900,454.
In 2029, EMBC is forecast to generate $63,005,474,088 in revenue, with the lowest revenue forecast at $60,512,451,732 and the highest revenue forecast at $64,875,240,855.